Putting the CAR(T) Before the Horse: Practicalities of T Cell-Activating Therapies in Multiple Myeloma


Register Now

Join us for a CME-certified VIRTUAL Friday Satellite Symposium preceding the 64th American Society of Hematology (ASH) Annual Meeting & Exposition.

Friday, December 9, 2022
8:00 AM – 10:00 AM CT   Scientific Program

Patients with multiple myeloma that is refractory to multiple classes of therapeutics can be particularly difficult to treat. Fortunately, the treatment landscape is expanding, and a range of new therapies for patients with multiply relapsed or refractory multiple myeloma (RRMM) is rapidly emerging. In particular, chimeric antigen receptor (CAR) T-cell therapy is a powerful new immunotherapy that has revolutionized cancer treatment and has been approved for patients with RRMM. However, the CAR T process is long and complex, with challenges associated with each phase of the process and unique adverse events. Also on the horizon are bispecific antibodies, another type of T cell–activating therapy that offers an off-the-shelf option that may be ideal for patients that need to initiate treatment quickly.

This symposium features evidence-based presentations along with patient cases designed to address the nuances of T cell–activating therapy use and, identification of patients that are the best candidates for these approaches, and options for patients who may not be candidates for this therapy.

Join the discussion on Twitter: #RMELiveMM

Hearn Jay Cho, MD, PhD—Program Co-Chair
Chief Medical OfficerMultiple Myeloma Research Foundation
Norwalk, Connecticut
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York
Paul G. Richardson, MD—Program Co-Chair
R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts
A. Keith Stewart, MBChB—Program Co-Chair
Professor of Medicine
University of Toronto
Medical Director
Princess Margaret Cancer Centre
Vice President Cancer
University Health Network
Toronto, Ontario, Canada
Amrita Y. Krishnan, MD, FACP
Executive Medical Director, Hematology, City of Hope Orange County
Director, Judy and Bernard Briskin Center for Multiple Myeloma Research
Professor, Department of Hematology and Hematopoietic Cell Transplantation
City of Hope Medical Center
Duarte, California
Suzanne Lentzsch, MD, PhD
Professor of Medicine
Director, Multiple Myeloma and Amyloidosis Service
Columbia University Medical Center
New York, New York


8:00 AM
Introduction and Overview
Hearn Jay Cho, MD, PhD—Program Co-Chairs
8:10 AM
CAR T-Cell Therapy Clinical Safety and Efficacy
Suzanne Lentzsch, MD, PhD
8:25 AM
Bispecifics Clinical Safety and Efficacy 
Amrita Y. Krishnan, MD, FACP
8:40 AM
Options for Patients Who May Not Have Access to CAR T or Bispecifics
Paul G. Richardson, MD
8:55 AM
Questions and Answers/Panel Discussion
9:10 AM
Case Studies
9:40 AM
Questions and Answers/Panel Discussion
9:55 AM
Concluding Remarks 
A. Keith Stewart, MBChB

Target Audience
This activity is designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care professionals involved in the care of patients with multiple myeloma.

Learning Objectives
At the conclusion of this activity, participants should be better able to:

  • Evaluate recent clinical advances in the use of T cell–activating therapies in patients with RRMM and their implications for clinical practice
  • Summarize the toxicity profiles of T cell–activating therapies used in the treatment of RRMM, particularly with respect to cytokine release syndrome (CRS), infections, and immune effector cell–associated neurotoxicity syndrome (ICANS)
  • Describe the unique aspects of manufacturing, bridging therapy, and the need for lymphodepletion associated with CAR T-cell therapies used to treat RRMM
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Penn State College of Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Jointly provided by       

Support for this activity has been provided through educational grants from Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Legend Biotech USA Inc.

This website is managed by RedMedEd, and RedMedEd’s printed privacy policy applies to this site. CME credit for this activity is provided by Penn State College of Medicine. Aggregated data concerning registrations, posttests, and evaluations may be shared, but RedMedEd will not knowingly share any personally identifiable information. The information you provide on this site may be used to contact you about your CME credit or other relevant educational activities provided through Penn State College of Medicine or RedMedEd. For more information, contact Penn State College of Medicine at ContinuingEd@hmc.psu.edu and reference activity code G6874-22-Z or RedMedEd at education@redmeded.com.